Floris Fauchet- PharmD, PhD
- Université Paris Cité
Floris Fauchet
- PharmD, PhD
- Université Paris Cité
About
8
Publications
613
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
128
Citations
Introduction
Skills and Expertise
Current institution
Publications
Publications (8)
The aims of this study were to describe the unbound and total lopinavir pharmacokinetics in pregnant women in order to: evaluate if a dosing adjustment is necessary during pregnancy. Lopinavir placental transfer was described and several genetic covariates were tested to explain its variability.
A total of 400 maternal, 79 cord blood and 48 amnioti...
The pediatric population is often exposed to drugs without sufficient knowledge about pharmacokinetics. The prediction of accurate clearance values in children, especially in neonates and infants, will improve the rational in dosing decisions. Drugs clearances from birth to adulthood were compiled after a systematic review of pharmacokinetic report...
Background:
Lopinavir/ritonavir (LPV/r) is available in a liquid formulation that is far from ideal for treatment of children in resource-poor settings. Flexible, low-cost, solid, oral fixed-dose combinations (FDC) of LPV/r with nucleoside reverse transcriptase inhibitors (LPV/r/abacavir [ABC]/lamivudine [3TC] and LPV/r/zidovudine [ZDV]/3TC) are n...
For the first time, a population approach was used to describe abacavir (ABC) pharmacokinetics in HIV-infected pregnant and
nonpregnant women. A total of 266 samples from 150 women were obtained. No covariate effect (from age, body weight, pregnancy,
or gestational age) on ABC pharmacokinetics was found. Thus, it seems unnecessary to adapt the ABC...
Aims:
The aims were to describe emtricitabine (FTC) pharmacokinetics in a large population of pregnant women during the different trimesters of pregnancy, and to explain FTC pharmacokinetic variability during pregnancy.
Methods:
FTC plasma concentrations were measured in 103 non-pregnant and 83 pregnant women, including women in the different tr...
AimsThe main goal of the study was to describe the pharmacokinetics of maternal zidovudine (ZDV) administrations during pregnancy and labor and to evaluate its impact on fetal concentrations and exposures.MethodsA total of 195 HIV-infected pregnant and non-pregnant women aged 16-59 years were included, 273 maternal and 79 cord blood ZDV concentrati...
The aims were to describe emtricitabine concentration-time courses in a large population of HIV-1-infected adults, to evaluate the influence of renal function on emtricitabine disposition and to evaluate current dosing adjustment recommendations. Emtricitabine plasma concentrations were collected from 161 adult patients during therapeutic drug moni...
The aims of this study were to describe the pharmacokinetics of zidovudine (ZDV) and its biotransformation to its metabolite, 3*-azido-3*-deoxy-5*-glucuronylthymidine (G-ZDV), in HIV-infected children, to identify factors that influence the pharmacokinetics of ZDV, and to compare and evaluate the doses recommended by the World Health Organization (...
